● pepmg Research Desk · Peer-reviewed evidence review
What the research says about sermorelin
A neutral summary of the peer-reviewed literature on sermorelin, a growth-hormone-releasing hormone analogue historically used as a diagnostic agent and studied in growth-hormone-deficient children. The modern research base is thin. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue (the first 29 amino acids of GHRH) historically studied as a diagnostic agent and as a treatment in growth-hormone-deficient children [1].
- In studied populations it stimulates release of the body's own growth hormone and raises IGF-1, a growth-hormone marker [1][2].
- The published research is thin and mostly older or observational, with no modern controlled trials for the anti-aging or body-composition uses for which it is now marketed [1][2].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What sermorelin is
Sermorelin is described in the literature as a 29-amino-acid analogue of human growth-hormone-releasing hormone, the shortest fragment that retains full biological activity, which stimulates growth-hormone secretion from the anterior pituitary [1]. Because natural GHRH has a very short plasma half-life (about 10 to 20 minutes), chemical strategies such as PEGylation have been explored to extend it [4]. Sermorelin is sold by third-party research-chemical vendors and, in that form, is offered for laboratory and research use only.
Historically, sermorelin was used clinically as a diagnostic test for growth-hormone deficiency and, in limited use, to treat some growth-hormone-deficient children [1].
What the human research has measured
Limited evidenceA review of sermorelin's clinical use reported that an intravenous dose served as a relatively specific diagnostic test for growth-hormone deficiency, and that once-daily subcutaneous sermorelin at bedtime was effective in promoting growth in some prepubertal children with idiopathic growth-hormone deficiency, with height-velocity increases sustained over 12 months and, in a few children, maintained to 36 months [1]. That same review noted that the height-velocity gains were smaller than those seen with recombinant growth hormone (somatropin) [1].
A small retrospective study in hypogonadal men using a growth-hormone-secretagogue regimen that included sermorelin reported a rise in the growth-hormone marker IGF-1, from a baseline mean of about 159.5 ng/mL to about 239.0 ng/mL after treatment (p<.0001) [2]. A physiology study in pregnant women examined how sermorelin affects maternal versus fetal growth-hormone secretion [3]. Together these describe hormone responses in specific settings rather than clinical outcomes in the general population.
What the trials report on safety and adverse events
Limited evidenceThe older clinical literature reported that single intravenous and repeated once-daily subcutaneous doses of sermorelin were generally well tolerated, with transient facial flushing and pain at the injection site being the most commonly reported adverse events [1]. These observations come from diagnostic use and small treatment series in children with growth-hormone deficiency, not from modern trials in healthy adults.
There are no controlled human trials establishing the safety or efficacy of sermorelin for the anti-aging, muscle, or fat-loss uses for which it is currently marketed. This is not medical advice; the human safety of sermorelin for those uses is not established. Consult a qualified professional and read the studies directly.
How strong is the evidence
Because the sermorelin evidence base is thin, largely older, and confined to diagnostic use and growth-hormone-deficient children, it is characterized as limited [1][2]. "Limited" describes the state of the research, not a judgment of whether sermorelin works or is safe, and it reflects the near-absence of modern controlled trials for its present-day marketed uses.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 4
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
- Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels.
- Perinatal growth hormone physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH.
- PEGylation of growth hormone-releasing hormone (GRF) analogues.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.